Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07583251 | Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients | PHASE1 | NOT YET_RECRUITING | 9 | — | — | Jun 1, 2026 | Feb 1, 2027 | May 13, 2026 | 1 | United States |
Safety: Creatinine not more than 1.5mg/dL, AST and ALT levels not more than 1.5 X ULN.
Safety and Tolerability
Safety and tolerability
Safety and tolerabitily
Safety and tolerability: The number of participants experiencing clinically significant abnormal laboratory test results (hematology, kidney, and liver function tests) during 3 months of GGC supplementation, compared with baseline.
| Arm | Type | Description |
|---|---|---|
| Gamma - Glutamylcystiene 400 | EXPERIMENTAL | Each participant will receive gamma-glutamyl cysteine (GGC) capsules orally 400mg once a day for 3 months. |
| Gamma - Glutamylcystiene 800 | EXPERIMENTAL | Each participant will receive gamma-glutamyl cysteine (GGC) capsules orally 400mg two times(morning-evening) a day for 3 months |
| Gamma - Glutamylcystiene 1200 | EXPERIMENTAL | Each participant will receive gamma-glutamyl cysteine (GGC) capsules orally 400mg three times (morning-afternoon - evening) a day for 3 months |
| Name | Type | Description |
|---|---|---|
| Gamma- Glutamylcysteine | DRUG | 400mg capsules once a day |
| Gamma- Glutamylcusteine | DRUG | 400mg capsules orally (three times) per day |
Inclusion Criteria: 1. Memory complaints; 2. MCI diagnosis 3. MoCA score between 18-25 4. Age 55 - 80 years old. 5. Ability to read and write in English Exclusion Criteria: 1. Subjects with acute head trauma or head injury involving loss of consciousness; 2. Subjects with a history of cancer; 3. ...